Equitable Holdings Series C Depositary Preferred (EQH-PC, 4.3% fixed, noncumulative, perpetual) trades at $16.39 against $25 par. Current yield 6.57%. A 10-K/A filed April 21, 2026 reframed the story — the amendment itself is routine, but its explanatory note laid out the preferred treatment in the pending EQH-Corebridge merger announced March 26. The question: does the 34% par discount reflect specific risk, or a generic complexity premium the market hasn't decomposed?

What the filing and merger documents say

The 10-K/A is a Part III amendment — cover page error-correction box unchecked, explanatory note states the filing "does not amend, update or change any other items or disclosures in the Original Report." The annual meeting is delayed because a special meeting on the Corebridge merger comes first.

The explanatory note spells out preferred treatment. Each share of EQH Series C Preferred converts 1-for-1 into "Series 1-C HoldCo Preferred Stock" with "substantially identical powers, preferences, privileges and rights." The merger agreement explicitly permits ordinary-course dividends of $268.750 per share per quarter ($0.269 per depositary share) through closing. NYSE listing maintained. No cash consideration, no redemption, no appraisal rights.

2025 STIC Free Cash Flow (subsidiary distributions to Holdings less Holdings expenses) was $2,600M vs $1,600M target. Series C annual obligation is $12.9M. Standalone 2025 coverage: 201x. 2026 normalized: ≈108x. Pro forma combined HoldCo preferred stack (Series A $42M + Series 1-C $12.9M + Series 2 from CRBG $34.4M = $89.3M) against combined distributable cash ($3.5-4.0B) implies 40-45x coverage.

CRBG's 8-K and 10-K mirror the disclosure with reciprocal "substantially identical" language for its Series A (6.875% fixed/reset noncumulative) converting to Series 2 HoldCo. Nippon Life signed a Voting and Support Agreement April 8, 2026 for 26.7% of CRBG (13D/A). Symmetric $475M termination fee. Outside Date December 26, 2026 with two 3-month auto-extensions.

What the market prices

$16.39 implies 6.57% current yield. Comparable IG perpetual preferreds from A-/BBB+ issuers currently yield 5.75-6.00%. The merger complexity premium embedded is 60-80 bps. Working backward, the market implies probability of clean close with rerating in the 20-25% range — our read is 40-50%. Options chains on single-issue preferreds are illiquid; no useful implied-P signal.

Why the gap exists

Primary holders of this issue are retail and income funds. "My 4.3% preferred is becoming a Series 1-C HoldCo Preferred Stock after an insurance merger with an asset manager client consent condition" triggers sell reflex faster than analysis. More specifically:

1. Primary-source confirmation of preferred treatment sits in the explanatory note of a 10-K/A most readers open looking for accounting changes.
2. E*TRADE/Morgan Stanley 2020 is the clean analog — preferred rolled cleanly into MS/PA and MS/PB with uninterrupted dividends. Retail doesn't cross-shop M&A precedent.
3. AllianceBernstein's 75% client consent condition reads unusual. Historical base rate for asset manager change-of-control consent is 88-95% of fees; EQH itself represents 16% of AB AUM pre-locked as consenting. That context isn't in headline summaries.
4. "Noncumulative" creates reflexive fear that 40-45x pro forma coverage should dissipate but doesn't.
5. 2024-25 rate selloffs conditioned preferred holders to sell on any uncertainty. Muscle memory, not decomposition.

Risks, ranked

1. Rate duration (largest). 14-16 year effective duration; 100bp rate rise is ≈15% price drop. No edge on Fed path.
2. S-4 Exhibit A-2 deviation. The actual Certificate of Designations hasn't been filed. "Substantially identical" has legal weight; the document decides.
3. HoldCo credit rating. Newly formed obligor is unrated at inception. S&P has negative outlook on EQH Holdings; combined entity could bring CRBG drag.
4. Merger termination. $475M symmetric fee, Nippon 26.7% lock — low probability. Failure is credit-neutral (EQH standalone 200x covered) but complexity unwind thesis weakens.
5. NY DFS approval timing. Empower/Prudential closed in 9 months; Nippon/Resolution Life 11 months multi-jurisdictional. Outside Date plus extensions gives runway to ~June 2027.

Catalysts

• Mid-July 2026 — Q3 dividend at full $0.269/share. Operational continuity check.
• July 31, 2026 (expected) — S-4 Registration Statement filing. Exhibit A-2 is the "substantially identical" verification. Single most important catalyst.
• Q3 2026 — S-4 effective, proxy mailed.
• Q4 2026 — EQH and CRBG special meetings; Nippon vote locks CRBG side.
• December 26, 2026 — Outside Date. Close = on schedule; delay = extensions.
• Q1-Q2 2027 — NY DFS approval expected; final gating item.
• ~June 2027 — Extended Outside Date.

What would change our mind

• S-4 Exhibit A-2 reveals a material deviation (reset feature added, mandatory call introduced, cumulative status changed).
• S&P downgrades EQH Holdings or pre-deal HoldCo to BBB or lower.
• CRBG 10-Q shows AB client consent tracking below 60% as the threshold approaches.
• NY DFS extends review beyond the June 2027 Outside Date.
• A comparable post-announcement insurance preferred trades at 5.75% yield with unresolved close uncertainty — evidence the complexity-premium read is wrong.

Evidence